Zentalis Pharmaceuticals (ZNTL)
(Delayed Data from NSDQ)
$4.02 USD
-0.04 (-0.99%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $4.02 0.00 (0.00%) 6:54 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Zentalis Pharmaceuticals, Inc. [ZNTL]
Reports for Purchase
Showing records 1 - 20 ( 76 total )
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Catalysts in 2H24 Look to Put Azenosertib Back on Track; Reit. Buy and $20 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Upgrading to NEUTRAL Based on Valuation Post Sell-Off
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Downgrading to UNDERPERFORM; Azeno Path Forward Unclear
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Azenosertib Poised for Multiple Readouts in 2024; Reit. Buy and Lowering our PT to $40
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Azenosertib is Primed for an Assault on Gynecologic Malignancies in 2024: Reit. Buy and $46 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; We?re Not Quite There, But the Cupboard Is Far from Bare
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for ZNTL 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Downgrading to NEUTRAL as Strategy Shifts for Azeno
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Azenosertib?s Positive Development Updates Cut Both Ways
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Azenosertib Furthers its Positioning Across Oncology; Reit. Buy and $55 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Azenosertib RP2D Dosing Identified, Onto Ph 3 Combo Study Next
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Now Two Steps Forward; Azeno Dose Optimization Pays Off
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R